Prolieve sells devices for the treatment of benign prostatic hyperplasia. The Prolieve technology was originally created and commercialized by the Medifocus scientific and management teams.
Medifocus will pay a total of $5 million for the business. Medifocus will pay Boston Scientific $2.5 million upon closing of the transaction and the remainder will be paid in quarterly installments contingent upon the sales performance of the Prolieve business, up to a maximum amount of $2.5 million.
Medifocus has its corporate office in Toronto, Ontario, Canada, and its operating office in Columbia, Md.
Related Articles on Acquisitions:
SRI/Surgical Express to be Acquired by Synergy Health
Boston Scientific Completes Acquisition of Cameron Health
Bausch + Lomb Completes Acquisition of ISTA Pharmaceuticals
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
